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Conclusions. Despite actual and theoretical problems 
with the use of amiodarone in children, this drug will remain, 
as it does in adults, the sole option for many patients. The 
decision to begin amiodarone therapy must be made only 
after careful consideration of late side effects and future 
surgery. Careful follow-up through adolescence and into 
adulthood is required, because side effects may develop 
insidiously. As devices and curative surgical procedures are 
developed and perfected, the need for long-term ant~~~~ytb~ 
mic drug therapy may diminish. 
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